T
Tarsus Pharmaceuticals Inc (TARS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$78.68
-1.60 (-1.99%)
Market Cap: $3.96B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tarsus Pharmaceuticals Inc (TARS) Valuation Multiples
Tarsus Pharmaceuticals (TARS) trades at 5.4x sales and 35.1x book value. Its P/S of 5.4x is below its 5-year median of 11.5x. Its forward P/E is 66.7x.
Current Multiples
Its free cash flow yield is 0.9%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 66.7x |
| Price to sales | 5.4x |
| Price to book | 35.1x |
| Price to FCF | 112.6x |
| EV/FCF | 110.6x |
| PEG | N/A |
| FCF yield | 0.9% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 5.4x | 11.5x | N/A |
| P/B | 35.1x | 4.2x | N/A |
Valuation History
Over the 5 of the 6 year ends shown that have a P/S, its P/S ranged from 7.6x in 2025 to 35.9x in 2023. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $81.88 | 7.6x | 10.2x |
| 2024 | $55.37 | 11.4x | 9.5x |
| 2023 | $20.25 | 35.9x | 3.3x |
| 2022 | $14.66 | 14.1x | 2.0x |
| 2021 | $22.50 | 8.1x | 2.8x |
| 2020 | $41.33 | N/A | 5.2x |
Frequently Asked Questions About TARS
What is TARS's forward P/E ratio?
Tarsus Pharmaceuticals has a forward P/E ratio of 66.7x.
What is TARS's price to sales ratio?
Tarsus Pharmaceuticals has a price to sales ratio of 5.4x.
TARS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors